Loading...
XHKG
8049
Market cap157mUSD
Dec 05, Last price  
2.19HKD
1D
-2.23%
1Q
3.79%
Jan 2017
35.19%
IPO
59.85%
Name

Jilin Province Huinan Changlong Bio-pharmacy Co Ltd

Chart & Performance

D1W1MN
XHKG:8049 chart
P/E
6.05
P/S
1.26
EPS
0.33
Div Yield, %
3.13%
Shrs. gr., 5y
Rev. gr., 5y
6.41%
Revenues
881m
+4.71%
81,889,00069,522,00097,284,000127,124,000152,766,000200,630,000274,294,000353,247,000457,746,000601,715,000539,134,000654,119,000645,303,000647,672,000645,885,000622,250,000705,456,000841,586,000841,545,000881,157,000
Net income
184m
+24.32%
8,017,0003,037,00012,378,00014,989,00022,076,00035,891,00050,893,00058,754,00079,274,000132,785,000117,638,000142,670,000144,402,000161,216,000144,726,000126,558,000143,283,000193,565,000148,207,000184,250,000
CFO
220m
-30.48%
17,841,00029,357,00017,096,00040,643,00014,397,00055,169,00022,909,00050,893,00082,694,00049,434,000151,613,000123,823,000146,507,000138,813,000132,509,000151,227,000215,090,000203,992,000315,947,000219,652,000
Dividend
Jun 18, 20240.06862 HKD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People's Republic of China. It offers tablets, capsules, pills, Chinese medicine pretreatment and extraction products, powders for injections, lyophilized powder for injections, small volume injection solutions, APIs, and granules. The company markets its products under the Changlong and Qing Tong brands. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited. Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Kowloon, Hong Kong.
IPO date
May 24, 2001
Employees
928
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT